Search research articles
Contact Us
Filters
Showing results (281-290 of 504) with videos related to
Page
of 51
Sort By:
Urology
|
February 8, 2012
Adoption of laparoscopic radical nephrectomy in the state of Washington
Jonathan D Harper, E Sophie Spencer, Michael P Porter, et al.
Journal of Cell Science
|
July 11, 2019
The interaction between CASK and the tumour suppressor Dlg1 regulates mitotic spindle orientation in mammalian epithelia
Andrew P Porter, Gavin R M White, Natalie A Mack, et al.
The Journal of Urology
|
September 25, 1997
Disease-free and overall survival after cryosurgical monotherapy for clinical stages B and C carcinoma of the prostate: a 20-year followup
M P Porter, C A Ahaghotu, S A Loening, et al.
The American Journal of Physiology
|
September 1, 1982
Stimulation of renin secretion by vasoactive intestinal peptide
J P Porter, I A Reid, S I Said, et al.
Gastroenterology
|
June 1, 1971
Fat absorption in bile fistula man. A morphological and biochemical study
H P Porter, D R Saunders, G Tytgat, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
February 15, 2014
Characterization of HIV-1 drug resistance development through week 48 in antiretroviral naive subjects on rilpivirine/emtricitabine/tenofovir DF or efavirenz/emtricitabine/tenofovir DF in the STaR study (GS-US-264-0110)
Danielle P Porter, Rima Kulkarni, Todd Fralich, et al.
Plos One
|
October 30, 2014
Leatherbacks swimming in silico: modeling and verifying their momentum and heat balance using computational fluid dynamics
Peter N Dudley, Riccardo Bonazza, T Todd Jones, et al.
Antiviral Therapy
|
January 17, 2017
Viral blips were infrequent in treatment-naive adults treated with rilpivirine/emtricitabine/tenofovir DF or efavirenz/emtricitabine/tenofovir DF through 96 weeks
Danielle P Porter, Rima Kulkarni, Will Garner, et al.
HIV Clinical Trials
|
March 18, 2015
96-week resistance analyses of the STaR study: rilpivirine/emtricitabine/tenofovir DF versus efavirenz/emtricitabine/tenofovir DF in antiretroviral-naive, HIV-1-infected subjects
Danielle P Porter, Rima Kulkarni, Todd Fralich, et al.
Archives of Physical Medicine and Rehabilitation
|
June 15, 2005
Impact of sitting time on seat-interface pressure and on pressure mapping with multiple sclerosis patients
Shelley A Crawford, May D Stinson, Deirdre M Walsh, et al.
Page
of 51
Search research articles
Search
Showing results (281-290 of 504) with videos related to
Sort By:
Page
of 51
Urology
|
February 8, 2012
Adoption of laparoscopic radical nephrectomy in the state of Washington
Jonathan D Harper, E Sophie Spencer, Michael P Porter, et al.
Journal of Cell Science
|
July 11, 2019
The interaction between CASK and the tumour suppressor Dlg1 regulates mitotic spindle orientation in mammalian epithelia
Andrew P Porter, Gavin R M White, Natalie A Mack, et al.
The Journal of Urology
|
September 25, 1997
Disease-free and overall survival after cryosurgical monotherapy for clinical stages B and C carcinoma of the prostate: a 20-year followup
M P Porter, C A Ahaghotu, S A Loening, et al.
The American Journal of Physiology
|
September 1, 1982
Stimulation of renin secretion by vasoactive intestinal peptide
J P Porter, I A Reid, S I Said, et al.
Gastroenterology
|
June 1, 1971
Fat absorption in bile fistula man. A morphological and biochemical study
H P Porter, D R Saunders, G Tytgat, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
February 15, 2014
Characterization of HIV-1 drug resistance development through week 48 in antiretroviral naive subjects on rilpivirine/emtricitabine/tenofovir DF or efavirenz/emtricitabine/tenofovir DF in the STaR study (GS-US-264-0110)
Danielle P Porter, Rima Kulkarni, Todd Fralich, et al.
Plos One
|
October 30, 2014
Leatherbacks swimming in silico: modeling and verifying their momentum and heat balance using computational fluid dynamics
Peter N Dudley, Riccardo Bonazza, T Todd Jones, et al.
Antiviral Therapy
|
January 17, 2017
Viral blips were infrequent in treatment-naive adults treated with rilpivirine/emtricitabine/tenofovir DF or efavirenz/emtricitabine/tenofovir DF through 96 weeks
Danielle P Porter, Rima Kulkarni, Will Garner, et al.
HIV Clinical Trials
|
March 18, 2015
96-week resistance analyses of the STaR study: rilpivirine/emtricitabine/tenofovir DF versus efavirenz/emtricitabine/tenofovir DF in antiretroviral-naive, HIV-1-infected subjects
Danielle P Porter, Rima Kulkarni, Todd Fralich, et al.
Archives of Physical Medicine and Rehabilitation
|
June 15, 2005
Impact of sitting time on seat-interface pressure and on pressure mapping with multiple sclerosis patients
Shelley A Crawford, May D Stinson, Deirdre M Walsh, et al.
Page
of 51